Phase I trials On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial. Phase II and III trials On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with<unk>  in healthy volunteers.
BBV154
OTL-103
HVTN 702
AP-7 
CoWIN
XPB
CARB-X
BGR-34